Global Mobile Tomography Market Anticipated to Garner $1,371.1 Million, Growing with 8.2% CAGR in the 2022–2031 Timeframe [240-Pages] | Depicted by Research Dive
March 21, 2023 09:05 ET | Research Dive
New York, USA, March 21, 2023 (GLOBE NEWSWIRE) -- Research Dive has published a new report on the global mobile tomography market. According to the report, the global market is projected to surpass...
Cytovation appoints Iman Barilero as Chief Development Officer
March 21, 2023 04:00 ET | Cytovation
Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
March 21, 2023 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Active Pharmaceutical Ingredients Market to hit USD 453.5 billion by 2032, says Global Market Insights Inc.
March 20, 2023 02:10 ET | Global Market Insights Inc.
Selbyville, Delaware, March 20, 2023 (GLOBE NEWSWIRE) -- Active pharmaceutical ingredients market value is estimated to surpass USD 453.5 billion by 2032, according to a new research report by...
Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs
March 17, 2023 07:00 ET | Predictive Oncology Inc.
EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private...
NOVARTIS logo.jpg
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
March 16, 2023 18:47 ET | Novartis Pharma AG
New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months...
Onconova Logo BLUE.jpg
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
March 16, 2023 16:04 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Global Computer-aided Drug Discovery Market Anticipated to Garner $7,504.7 Million, Growing with 11.48% CAGR in the 2022–2030 Timeframe [240-Pages] | Details by Research Dive
March 16, 2023 09:00 ET | Research Dive
New York, USA, March 16, 2023 (GLOBE NEWSWIRE) -- Research Dive has published a new report on the global computer-aided drug discovery market. According to the report, the global market is projected...
PDS Biotech Logo.png
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results
March 16, 2023 08:00 ET | PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Surface Logo_rgb[3].jpg
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023 
March 16, 2023 08:00 ET | Surface Oncology, Inc.
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...